By Sarina Isaacs
Shares of ARS Pharmaceuticals were sharply higher after the biopharmaceutical company posted earnings and revenue that came in well above Wall Street views.
The stock was up 22% at $14.22 in early trading. That puts it at a gain of more than 60% over the past 12 months.
The San Diego-based biopharmaceutical company, whose main product is an emergency nasal spray for severe allergic reactions, on Thursday reported a profit of $49.9 million, or 48 cents a share.
Analysts were anticipating a loss of 24 cents per share, and a year earlier the company said it lost $7.2 million.
Revenue for the quarter came to $86.6 million, surpassing analyst expectations for $5.7 million.
ARS said its neffy nasal-spray product brought in $7.3 million in net revenue from its late-September launch through the end of the year.
The company added that, with $314 million in cash, cash equivalents and short-term investments as of Dec. 31, it continues to expect its financial position to support its operating plans for at least the next three years.
Write to Sarina Isaacs at sarina.isaacw@wsj.com
(END) Dow Jones Newswires
March 20, 2025 10:03 ET (14:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。